Introduction
The Integrated Stress Response (ISR) is a coordinated cellular program induced by cells to adapt to a multitude of stresses, including ER stress, hypoxia, low glucose, and amino acid deprivation (Kaufman, 2002; Lee, 1992) . There are four known kinases that regulate the ISR: PERK (PKR-like endoplasmic reticulum kinase), GCN2 (general control non-derepressible 2), PKR (double stranded RNA activated protein kinase) and HRI (heme-regulated inhibitor kinase).
PERK is a transmembrane ER protein that is activated by factors that induce ER stress, such as low glucose, hypoxia and unfolded proteins, whereas GCN2 is a cytoplasmic protein that is responsible for sensing low levels of amino acids (Shi et al, 1998; Wek et al, 1995) . The others are HRI, which is activated by heme deficiency, and PKR, a kinase regulated by double stranded RNA (Chen, 2000; Levin et al, 1980) . When any of these four kinases are activated, they can phosphorylate the translation initiation factor eIF2α (Blais et al, 2004; Koumenis et al, 2002) . Phosphorylation of eIF2α results in general translation inhibition; however, a group of stress-response genes are translationally upregulated due to ribosome initiation at an alternate upstream open reading frame (Harding et al, 2000a; Shi et al, 1998; Vattem & Wek, 2004) . ATF4 is one of these genes, and it is of particular interest as it modulates the expression of genes involved in oxidative stress mitigation, amino acid synthesis, and uptake of nutrients (Blais et al, 2004; Harding et al, 2003; Vattem & Wek, 2004) . It has been demonstrated by our group and others that the levels of ATF4 protein are increased in tumor cells as compared to normal tissue and that ablating the expression of this protein significantly decreases the mass of xenograft tumors in mice (Ameri et al, 2004; Bi et al, 2005; Ye et al, 2010) . It has also been shown that ATF4 expression colocalizes with hypoxic regions in both murine and human tumors (Ameri et al, 2004; Bi et al, 2005) . However, while phosphorylation of eIF2α and upregulation of ATF4 can enhance cell survival, hyperactivation of this signaling pathway can lead to permanent cell growth arrest or cytotoxicity due to cell prolonged inhibition of protein synthesis. We have previously shown that upregulation of ISR signaling potentiates the cytotoxicity of the proteasome inhibitor bortezomib, a drug known to activate the unfolded protein response (UPR) (Fels et al, 2008; Obeng et al, 2006) . In addition, extensive or prolonged activation of the ISR leads to the ATF4-dependent upregulation of CHOP, a pro-apoptotic protein (Friedman, 1996; Harding et al, 2000a) . Cell growth arrest by overactivation of the ISR has been attributed to PERK-and eIF2α-dependent inhibition of cyclin D1, a key regulator of cell cycle progression (Brewer & Diehl, 2000) .
Based on these observations that ATF4 plays an important role in cancer cell survival, we sought to identify compounds capable of modulating the expression of ATF4 (both inhibitors and activators). For this, we used a construct consisting of the 5' untranslated region (UTR) of the ATF4 mRNA fused to the luciferase gene. This reporter construct allowed us to use luciferase activity as a surrogate for ATF4 mRNA translation. Screening of over 160,000 small molecules from the Specs, Chembridge, ChemDiv and ChemRX chemical libraries resulted in the identification of a compound that caused the upregulation of ATF4 translation. Additional studies on this compound, E235, revealed potent anti-proliferative activity against many transformed cells. Interestingly, E235 failed to upregulate ATF4 activity in normal, untransformed human diploid fibroblasts. Further analysis revealed that E235 causes cellular senescence in a p53-and p21-independent manner, as well as a G2/M cell cycle arrest, also in a p21-independent manner. Knockdown of ATF4 did not substantially affect senescence, but it increased overall cytotoxicity induced by E235.
Our results demonstrate that E235 is a potent activator of cellular senescence in a p53-and p21-independent manner in various transformed cells. Moreover, our results have uncovered a novel link between cellular senescence and activation of the ISR and show that ATF4 induction can be used as a readout in small molecule screens for novel senescence inhibitors with anti-tumor potential.
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Materials and Methods

Chemicals
E235 (E235-1756) was obtained from ChemDiv (San Diego, CA). The E235 chemical structure was drawn using KnowItAll® Informatics System from Bio-Rad (Hercules, CA). All cell culture reagents were from Gibco, except MEM (minimum essential medium), which was from Mediatech (Manassas, VA). Thapsigargin (Tg), puromycin, MG132, and nocodozole were purchased from Sigma-Aldrich (St. Louis, MO). Staurosporine was from MP Biomedicals (Solon, OH).
Cell culture and generation of stable cell lines
HT1080 human fibrosarcoma cells were obtained from ATCC (Manassas, VA), B16F10 mouse melanoma cells were a gift from Dr. Sandra Ryeom (University of Pennsylvania, Philadelphia, PA), p21-/-MEFs were a gift from Dr. Charles Scherr (St. Jude's Children's Hospital, Memphis, TN), p53-/-MEFs were a kind gift from the lab of Dr. Scott Lowe (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), and 4T1 mouse mammary carcinoma cells were a gift from Steve Albelda (University of Pennsylvania, Philadelphia, PA). These cells were cultured in Dulbecco's modified Eagle medium (DMEM). RPMI-8226 human multiple myeloma cells (ATCC) were grown in RPMI. Mouse adult lung fibroblasts (ALFs) were isolated in our lab from adult female mice (C57BL/6J, Jackson Laboratory, Bar Harbor, ME) and cultured in DMEM/F12. In all cases, the media was supplemented with penicillin, streptomycin, and 10% fetal bovine serum (FBS). AG1522 cells (Coriell Cell Repository, Camden, NJ) were grown in MEM supplemented with penicillin, streptomycin, 15% FBS, and non-essential amino acids (NEAA). HT1080 shATF4 cells were also supplemented with NEAA, as well as 55μM β -mercaptoethanol. To establish cells with stable knockdown of p21, B16F10 cells were transfected with pLKO or pLKO-shP21 plasmids (Sigma-Aldrich) using Lipofectamine2000 (Invitrogen, Grand Island, NY) and selected This article has not been copyedited and formatted. The final version may differ from this version. 
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7 with puromycin (2μg/ml and reduced to 0.5 μ g/ml for maintenance). HT1080 empty lentiviral vector and shPERK cells were grown with 0.5μg/ml puromycin to maintain plasmid expression.
Chemical library screen
The ATF4-Luc fusion gene construct was used in the screen (see results section). 4000 cells/well were plated for 24 hrs in 384 well microplate format prior to induction of ER stress with Thapsigargin (250nM) for 16h and exposure to one compound per well (10-20μM).
Luciferase reporter assay
HT1080 cells expressing either a constitutively active CMV-driven luciferase plasmid (CMV-Luc) or a plasmid where the expression of the luciferase gene was driven by the 5'-UTR of the ATF4 mRNA (ATF4-Luc) were seeded in a 24-well plate, and then treated in duplicate the following day. After 4 or 8 hours of treatment, luciferase activity was quantified using the Luciferase Assay System from Promega (Madison, WI). Each well was read in triplicate in a white 96-plate.
Luciferase activity in the ATF4-Luc cells was normalized to the activity in the corresponding CMV-Luc cells.
Immunoblot analysis
Immunoblotting was performed as previously described (Koumenis et al, 2002) , with the exception that proteins were transferred to polyvinylidene fluoride membranes. Protein concentration was determined using Pierce® 660 nm Protein Assay Reagent (Thermo Scientific, Waltham, MA), in accordance to the manufacturer's instructions. Primary antibodies against the following proteins were used: ATF4, p53, p21 (Santa Cruz Biotechnology, Santa Cruz, CA), Ku80, eIF2α, PERK, 
Real-time quantitative PCR
RNA was isolated by using TRIzol® Reagent (ambion, Carlsbad, CA) and following the protocol provided with it. Reverse transcription was performed using AMV Reverse Transcriptase (Promega). Real-time quantitative PCR was done using Power SYBR® Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) and was analyzed with the Applied Biosystems 7300 RealTime PCR System. PCR primers were purchased from Invitrogen. The following primers were used: human XBP1s-F: 5'-CCGCAGCAGGTGCAGG, and XBP1s-R: 5'-GAGTCAATACCGCCAGAATCCA; human 18s rRNA-F: 5'-CAATTACAGGGCCTCGAAAG, and 18s rRNA-R: 5'-AAACGGCTACCACATCCAAG.
Cell viability assay
Cell viability was analyzed using the Cell Proliferation Kit I (MTT assay) (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's protocol. Briefly, cells were seeded at low density in 24-well plates, and then treated in duplicate the following day. Once the DMSOtreated cells reached confluence, the MTT assay was started. To assess the effect of treatment length on cell viability, cells were plated at low density and treated for various lengths of time.
The media with E235 was then removed and replaced with normal media and cells were allowed to proliferate until the untreated cells reached confluency (5 days after initial treatment).
Each well was read in triplicate in a 96-well plate at absorbances of 550 and 690nm.
Live cell imaging
Cells were seeded at low density on 8-well chambered cover glass slides. Cells were viewed with a Leica AF6000 microscope (Wetzlar, Germany) at 37°C with 5% CO 2 , and still images were captured every 20 minutes for 50 hours. Images were viewed and analyzed with Leica Application Suite AF.
SA-β-galactosidase staining
Staining for senescence-associated β -galactosidase (SA-β-gal) activity was performed using the 
Clonogenic survival assay
Cells were plated at high density and allowed to attach overnight. They were then treated with E235 for 24 hours, at which time the cells were trypsinized and reseeded at low density in media without E235. The cells were incubated at 37°C for several days until colonies were of sufficient size to count. The colonies were fixed with 10% methanol/10% acetic acid and then stained with 0.4% crystal violet. Colonies were scanned and counted with an Oxford
OptronixGelCount™ and its accompanying software (Oxford, UK).
Cell cycle analysis
Cells were treated with DMSO or E235 for 8h, 16h, or 24h and then harvested with trypsin.
Harvested cells were washed, resuspended in PBS with 1%FBS, and fixed with cold ethanol.
Fixed cells were washed, incubated in phosphate-citric acid buffer for 5 minutes and then resuspended in PI/RNase solution (PBS, RNase, and 50μg/ml propidium iodide) for staining.
This article has not been copyedited and formatted. The final version may differ from this version. this drug on ATF4 protein expression (Fig.1B) . E235 caused a dose-dependent increase in luciferase activity from a reporter plasmid containing the 5' UTR of the ATF4 mRNA fused to the luciferase gene (Fig. 1A,C) . To confirm that this increase in luciferase activity corresponded to an increase in ATF4 protein levels, nuclear extracts from HT1080, B16F10, and AG1522 cells treated with increasing doses of E235 were subjected to immunoblotting. A dose-dependent increase in ATF4 protein levels was seen only in the HT1080 and B16F10 cells (Fig. 1D,E ).
There was no appreciable induction of ATF4 protein in the normal diploid AG1522 human fibroblasts in response to E235, whereas thapsigargin induced a potent upregulation of ATF4 levels ( Fig. 1F) , suggesting that this effect is restricted to transformed cells.
E235
Activates the ISR in Transformed Cells. Next, we analyzed the effects of E235 on the induction of the UPR and the ISR, since ATF4 is a common downstream effector of these two
pathways. An intermediate dose of 1μM E235 was added to HT1080 cells for various lengths of time. HT1080 cells were also treated with increasing doses of E235 for 4h. There was a timeand dose-dependent induction of p-eIF2α in response to E235 ( Fig. 2A,B) . However, in contrast to thapsigargin, E235 failed to induce any significant change in the electrophoretic mobility of PERK. In agreement with the ATF4 results, this dose-dependent increase in p-eIF2α was not seen in the AG1522 cells (Fig. 2C ). To determine if E235-mediated phosphorylation of eIF2α was a consequence of the activation of the UPR, the levels of spliced XBP-1 (XBP-1s) mRNA in HT1080 cells treated with E235 were evaluated by quantitative PCR. A very modest increase in XBP-1s was seen at 4h, but this was much less than the levels induced by thapsigargin, which suggested that E235 is acting primarily through the ISR (Fig. 2D ). To determine if the E235-induced phosphorylation of eIF2α was PERK-dependent, immunoblotting for total PERK and p- 
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). Moreover, we tested whether the activation of the ISR was due to inhibition of the proteasome by treating HT1080 cells with various doses of E235 and comparing the levels of ubiquitinated proteins to those in cells treated with the known proteasome inhibitor MG132 (Fig.   S1A ). Minimal accumulation of ubiquitinated proteins was seen with even the highest concentration of E235, indicating that proteasomal activity was not being inhibited at doses which induce ATF4 expression.
E235 Inhibits Cell Proliferation. Previously, it was shown that while induction of ATF4 is generally cytoprotective, prolonged or excessive activation of the UPR and ISR can be cytotoxic (Fels et al, 2008; Zinszner et al, 1998) . Thus, several transformed cell lines were treated with E235 and then subjected to an MTT viability assay. All four of the cancer cell lines tested exhibited a significant decrease in survival when treated with low μ M concentrations of E235.
E235 caused a dose-dependent decrease in cell viability in the HT1080 cells (Fig. 3A) .
Treatment with 1μM E235 decreased cell viability by over 75% in the B16F10 and 4T1 cells (Fig. 3A) . A dose of 10μM E235 essentially blocked the growth of all four cell types. Trypan blue exclusion assays performed under similar conditions on HT1080 and B16F10 cells confirmed that E235 dose-dependently decreases cell viability (data not shown). Notably, doses as low as 0.25μM were sufficient to eliminate cell survival in the RPMI-8226 cells (Fig. 3A) . In a clonogenic survival assay, 24h of 1μM E235 treatment completely prevented the formation of any colonies (Fig. S1B ). In addition, HT1080 cells demonstrated a time-dependent decrease in cell viability, with 24h of E235 treatment reducing viability by more than 50% (Fig. 3B) .
Treatment of RPMI-8226 cells with E235 for just 8h was enough to abolish any cell survival (Fig.   3B) . A dose dependent reduction in cell proliferation was also seen in the normal AG1522 cells, with 1μM E235 causing a 60-70% decrease in viability (Fig. 3C ). To determine whether the observed decrease in cell viability was due to apoptosis, HT1080 and B16F10 cells were treated with E235 for various times and doses and the cleavage of PARP (c-PARP) and the processing of caspase3 were examined by immunoblotting. While there was a modest increase in the 19kDa cleavage product of caspase3 in the HT1080 cells with E235, there was no significant accumulation of the 17kDa subunit, which was observed in the staurosporine-treated HT1080 cells (Fig. 3D ). In the B16F10 cells treated with E235 for 24h, there was a small increase in caspase3 cleavage with increasing dose (Fig. 3E) . In both cell lines, the levels of cleaved PARP in E235-treated samples remained the same as those in untreated controls. Together, these results suggest that apoptosis has a minimal contribution to the decrease in cell viability and proliferation induced by E235.
ATF4 Dependence of E235-Induced Effects.
Because we have shown that treatment with E235 increases ATF4 expression, we sought to determine if cell viability during E235 treatment was dependent on ATF4 expression. An MTT assay was performed on E235-treated HT1080 cells stably transfected with either non-targeting shRNA (shNT) or shRNA directed at ATF4 (shATF4) (Fig. 4A ). We observed a substantial decrease in cell viability in shATF4 cells compared to shNT cells at E235 doses of 0.5 and 1μM (Fig. 4B ). In agreement with these results, a significant decrease in shATF4 cell viability compared to shNT cells was seen with low doses of E235 treatment in a clonogenic survival assay (Fig. 4C) . However, 10μM doses of E235 eliminated cell survival in both shNT and shATF4 cells. Altogether, these results indicate that the induction of ATF4 confers cytoprotection to cells treated with low
E235 is a Potent Inducer of Cellular Senescence. While assaying the antiproliferative effects of E235 on transformed cells, we observed that cells treated for at least 48h with lower doses of E235 (0.25-1μM) increased in size and displayed characteristics consistent with a senescent phenotype (Fig. 5A) . A small augmentation of cell size was also seen in normal mouse and human cells, but it was not as extensive as that observed in the transformed cells (Fig. 5A,   S1C ). We therefore assayed for SA-β-gal activity, a commonly used senescence marker. Both To further examine the possibility that E235 induced senescence, levels of the cyclindependent kinase inhibitors (CDKI) p16, p21, and p27 with and without E235 treatment were assessed at various time points. Increased expression of these CDKIs has been correlated to the induction of cellular senescence (Ewald et al, 2010) . Both HT1080 and B16F10 cells displayed elevated levels of p21 with 1μM E235 at 8 and 16h (Fig. 5B,C) . In addition, a dosedependent increase in p21 protein expression was seen with 24h of E235 treatment in the HT1080 cells (Fig. 5B) . However, there was no appreciable difference in p27 levels in either cell type at any time point or any dose of E235 (Fig. 5B,C) . We also did not observe any changes in p16 expression at either 24 or 48h after E235 treatment in the HT1080 cells (Fig. S1D ).
E235-Induced Senescence is not Dependent on p21 or p53. Since E235 was shown to
induce p21 protein expression, we wanted to investigate the role of p21 in E235-induced cellular senescence. B16F10 cells were transfected with a plasmid expressing shRNA directed at p21 (shP21) or with an empty vector plasmid (pLKO), and near complete knockdown of p21 was confirmed by Western blotting (Fig. S2A) . These cells were then stained for SA-β-gal activity This article has not been copyedited and formatted. The final version may differ from this version. after 48h of treatment with low doses of E235. Unexpectedly, shP21 cells were still able to assume senescence-like morphology and to exhibit staining for SA-β-gal activity (Fig. 5D ).
However, the p21 knockdown cells still showed a small induction of p21 protein expression after E235 treatment, which could have been sufficient for senescence to occur (Fig. S2A) . To further test the role of p21, we treated p21+/+ and p21-/-MEFs with E235. We observed no difference in the ability of p21-/-vs. p21+/+ MEFs to undergo senescence (Fig. S2B) . Nevertheless, there was a significant reduction in cell viability in two separate clones of shP21 cells treated with E235 (0.5 or 1μM) compared to pLKO-transfected controls (Fig. 5E ). These results indicate that p21 plays a role in cellular survival but not senescence in E235-treated cells.
Because p53 is frequently involved in, although not absolutely required for, induction of cellular senescence (Ben-Porath & Weinberg, 2005; Chang et al, 1999) , we tested the effects of E235 on p53 wild-type and knockout Ras-and myc-transformed MEFs. Interestingly, p53 was also found to be dispensable for E235-induced senescence, as p53 knockout cells retained their ability to senesce under low doses of E235 (Fig. S2C ).
E235 Induces a G2/M Arrest. Consistent with the induction of senescence, we also observed that low doses of E235 caused cells to undergo G2/M arrest. The percentage of HT1080 cells in the G2/M phase of the cell cycle was significantly increased by E235 treatment, starting as early as 8h and becoming more evident at 16 and 24h (Fig. 6A ). This E235-induced increase of cells in G2/M was accompanied by a concomitant reduction of cells in S phase, with only 14.5% of E235-treated cells in S phase at 24h compared to 38.8% of DMSO-treated cells (Fig. 6A) . A small rise in the amount of cells in G1 was also observed. In addition, a substantial increase of cells in G2/M and concurrent decrease in S phase cells was seen even at 8h when B16F10 cells were treated with E235 (Fig. 6B ).
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corresponded to an increase in p53 protein levels in both normal (AG1522) and transformed (HT1080) cells (Fig. 7A) . We also analyzed the phosphorylation of p53 at Ser15, which is associated with activation of the DNA damage response (Chao et al, 2000) . In AG1522 cells, 1μM E235 induced a small amount of Ser15 phosphorylation, while 5 and 10μM doses produced p-Ser15 levels comparable to those seen in cells treated with 4Gy (Fig. 7B) . We also observed a dose-dependent increase in p-Ser15 levels in E235-treated HT1080 cells (Fig. 7B ).
Levels of p-Chk2 and
γ -H2AX were then examined to see if treatment with E235 also led to activation of the DNA damage response. In HT1080 cells, there was a significant induction in phosphorylation of H2AX with increasing doses of E235 (Fig.7C ). This effect was significantly attenuated in AG1522 cells, where a concentration of at least 5μM E235 was required to see any γ -H2AX (Fig. 7C) . Interestingly, the induction of γ -H2AX by E235 was attenuated in HT1080 cells expressing shATF4, suggesting that the DNA damage signaling could be partially dependent on ATF4 expression (Fig. 7E) . E235 treatment caused an increase in the levels of phosphorylated Chk2 in both synchronized (with nocodazole) and unsynchronized HT1080 cells (Fig. 7D) . The induction of the DNA damage response was not due to the generation of reactive oxygen species (ROS), however, even in cells treated with doses of up to 10μM E235 (Fig.   S2D ). To determine whether the activation of DNA damage response signaling was due to physical DNA damage, a comet assay was performed on AG1522 and HT1080 cells. E235 did not lead to DNA strand breaks in the AG1522 cells, as evidenced by the similar tail moments between the DMSO-treated and E235-treated cells (Fig. 7G ). Even more surprising was the finding that E235 did not cause an increase in tail moment in the HT1080 cells, despite the high This article has not been copyedited and formatted. The final version may differ from this version. levels of p53, Chk2 and H2AX phosphorylation (Fig. 7F,G) . Therefore, E235 appears to elicit a DNA damage response without inducing physical DNA damage.
Discussion
It has been previously demonstrated that inhibition of the ISR pathway, whether by inhibiting PERK activity, eIF2α phosphorylation, or ATF4 expression, sensitizes cells to ER stress (Harding et al, 2000b; Scheuner et al, 2001; Ye et al, 2010) . This sensitization is due to the accumulation of unfolded proteins in the ER and results in an increase in the levels of apoptosis (Koumenis, 2006) . However, a key aspect of the ISR is that under certain biological contexts (e.g., hyperactivation by pharmacological agents, prolonged activation, etc.), it can also lead to cytotoxicity. With sustained activation of the ISR, cells can undergo permanent cell growth arrest by PERK-dependent inhibition of cyclin D1 (Brewer & Diehl, 2000) . Alternatively, overactivation of the ISR can lead to cell death due to inhibition of protein synthesis and/or ATF4-mediated induction of the pro-apoptotic protein CHOP (Friedman, 1996; Harding et al, 2000a; Harding et al, 2000b) . Our group has previously shown that have shown that hypoxia, a physciological activator of ER stress, increases the sensitivity of HeLa cells to the ER-stress inducing agents thapsigargin and bortezomib (Fels et al, 2008) .
In this manuscript, we describe the identification of a novel, potent activator of cellular senescence, E235. The ISR and the UPR are increasingly being recognized as attractive targets for antitumor agents. Our screen was not able to identify any effective inhibitors of the PERK-eIF2α-ATF4 arm of the ISR. This may have been because the number of compounds screened was moderate (65,000), compared to larger, more encompassing chemical libraries. It is possible that screening of additional libraries may reveal specific inhibitors of this pathway.
No specific inhibitors of this pathway have yet been reported in the literature.
We did, however, identify a potent activator of ATF4 expression with our screening assay. This compound, E235, was active at high nM to low ATF4-Luc activity and ATF4 protein expression in a variety of human and mouse transformed cells. Intriguingly, E235 was unable to induce robust upregulation of eIF2α phosphorylation or ATF4 expression in untransformed human diploid fibroblasts. This finding suggests that the mechanism of ISR activation by E235 is tumor cell-specific. Moreover, E235 displayed potent anti-proliferative activity against transformed cell lines without causing significant apoptosis.
Rather, careful analysis of the effects of E235 using time-lapse microscopy revealed that it induced cellular senescence. This effect extended to the normal human fibroblasts. However, since normal tissues are not rapidly proliferating in vivo, and given the lack of any direct cytotoxicity by E235, we believe that in vivo this agent should display low toxicity towards normal tissues.
One caveat that must be considered is the fact that senescent cells can both suppress and promote tumor formation (Rodier & Campisi, 2011) . Traditionally, senescence is considered to be anti-tumorigenic, as it suppresses two of the major hallmarks of cancer cells: expanded growth potential and the ability to continue proliferation in the presence of activated oncogenes (Hanahan & Weinberg, 2000) . The results of several studies support this, demonstrating that senescent cells are commonly present in premalignant lesions but decrease in frequency in malignant tumors (Bartkova et al, 2005; Braig et al, 2005; Chen et al, 2005; Collado et al, 2005; Michaloglou et al, 2005) . On the other hand, senescent cells have been shown to secrete many factors that promote tumor progression, such as interleukin-6 and -8 and matrix metalloproteases, which can stimulate basement membrane invasion, and vascular endothelial growth factor A and growth-related oncogene α , angiogenesis-inducing factors (Coppé et al, 2006; Coppé et al, 2010; Coppé et al, 2008; Kang et al, 2003; Ksiazek et al, 2008; Millis et al, 1992) . the stress induced by E235. Also, as we have shown that shP21 cells are more sensitive to E235, p21 upregulation by DNA damage signaling may contribute to the cytoprotective role of ATF4. Hence, the increase in clonogenic cell death in ATF4 knockdown cells could be attributed to a decrease in DNA damage signaling, resulting in reduced p21 induction (Fig. S2E) .
Additional studies will be essential to confirm this and to further elucidate the effects of E235-mediated ATF4 induction on overall survival.
Although we have eliminated several potential mechanisms for induction of senescence by E235, such as induction of p21 or ATF4, inhibition of Aurora A (not shown), and induction of ROS, we still do not know exactly how E235 elicits its pro-senescence effects. It is possible that it may affect the process of DNA replication without inducing DNA damage or it could be a histone deacetylase inhibitor. A panel of over 400 known kinases was screened to determine if E235 exhibited inhibitory activity against any specific kinases (KINOMEscan, a division of DiscoveRx, San Diego, CA) (results not shown), but it did not reveal any significant activity against any kinase known to be involved in cell cycle regulation. We are in the process of investigating further the mechanism by which E235 induces senescence.
In summary, our results show that E235 induces ATF4 expression and establish a link between increased expression of ATF4 and the induction of DNA damage signaling. Further studies will need to be conducted to elucidate the mechanism by which E235 stimulates ATF4 expression and to determine the connection between ATF4 upregulation and the induction DNA damage signaling. Also, based on these promising in vitro results, we plan to begin studies in mice. The maximum tolerated dose of E235 and the effects of E235 on the growth of subcutaneous tumors will be examined.
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shNT or shATF4 cells. Cells were treated with various doses of E235 for 5 days. All E235 treatment groups were normalized to DMSO-treated (0μM) controls. **p<0.01 or ***p<0.001 as compared to 0μM controls using one-way ANOVA with Tukey's multiple comparison post-test.
C, The influence of ATF4 expression on the viability of cells treated with E235 was also analyzed with a clonogenic assay. Surviving fraction of each cell type is plotted vs. the log of the E235 concentration. Each data point is n=3. ***p=0.0003 for shNT vs. shATF4 at 1μM E235 by student's t-test. 
